Globe Roche Logo

Roche launches cobas® CT/NG on the cobas® 6800/8800 Systems in markets accepting the CE mark

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE-IVD launch of cobas® CT/NG, for use on the cobas® 6800/8800 Systems for the direct detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) DNA in both symptomatic and asymptomatic individuals. …

Explore

cobas® CT/NG

With STI rates on the rise, cobas® CT/NG provides a solution to meet the growing demand for CT/NG Testing, delivering exceptional assay performance, providing broader information for improved patient care decisions, and enabling simplicity and flexibility to support varying throughput …

More

Roche receives FDA approval for fully automated blood screening assay on the cobas® 6800/8800 Systems

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas® MPX test for use on the cobas® 6800 and 8800 Systems. The cobas® MPX test enables …

Explore

Roche HIV Global Access Program expands to include next-generation automated platform solutions

High throughput cobas® systems help optimize workflow for resource-limited settings Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion…

Explore

cobas® DPX

The cobas® DPX test, for use on the cobas® 6800 and 8800 Systems, is a multi-dye, duplex…

More

cobas® HBV for use on the cobas® 6800/8800 System

cobas® HBV is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human EDTA plasma or serum of HBV-infected individuals.

More

cobas® HCV for use on the cobas® 6800/8800 Systems

Quantitative nucleic acid test designed to deliver high sensitivity to meet the requirements of current…

More

cobas® HEV

Qualitative, real-time PCR test for the direct detection of hepatitis E virus (HEV) in human plasma.

More

cobas® HIV-1 for use on the cobas® 6800/8800 System

Nucleic acid amplification test for the quantitation of HIV-1 in EDTA plasma that targets two unique regions…

More

cobas® MPX

Detects and discriminates the most critical viral targets in one easy-to-use assay.

More

cobas® WNV

Detects mosquito borne TTID to provide extra level of safety

More

Roche receives FDA approval for HIV-1 viral load test on the cobas® 6800/8800 Systems

HIV-1 test expands menu for highly automated molecular platforms that offer fastest time to results.

Explore

Roche receives FDA approval for viral load tests and cobas® 6800/8800 Systems

Roche receives FDA approval for viral load tests and cobas® 6800/8800 Systems. cobas®6800/8800 Systems offer fastest time to results and highest throughput of any molecular platform, helping to improve disease management and patient care.

Explore

Roche launches next-generation duplex test for parvovirus B19 and hepatitis A in markets accepting the CE mark

Cobas® DPX assay increases safety of human plasma and plasma products

Explore

Roche launches next-generation viral load assay for HBV in markets accepting the CE mark

Cobas HBV assay offers unparalleled performance on the cobas 6800/8800 Systems

Explore

Roche launches next-generation viral load assay for CMV in markets accepting the CE mark

cobas® CMV assay offers unparalleled performance on the cobas® 6800/8800 Systems.

Explore

Roche launches next-generation viral load testing assays for new molecular diagnostic platforms in markets accepting the CE mark

cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems.

Explore

Roche launches new fully automated molecular diagnostic systems offering the fastest time to results with the highest testing capacity

The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays.

Explore